🏛️ Verified NIH Record • Updated 2025-04-09

A Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma (RENAVIV) (NCT03592472)

A Randomized, Phase 3, Double-blind, Placebo-controlled Study of Pazopanib With or Without Abexinostat in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma(RENAVIV)

🟢 Recruiting Phase3 💊 Investigational Drug / Biologic Sponsor: Xynomic Pharmaceuticals, Inc.

🩺 Plain-English Summary (8th-Grade Level)

This is a randomized, Phase 3, double-blind, placebo-controlled study of pazopanib plus abexinostat versus pazopanib plus placebo in patients with locally advanced unresectable or metastatic renal cell carcinoma (RCC).

Who can join: To join this study, participants generally need to meet the listed inclusion criteria (10 items) and avoid the listed exclusions (9 items).

Location: University Of UA Cancer Center(UACC)/DH-SJHMC — Phoenix, Arizona

Age range: 18 Years

🧪 Interventions in This Study

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

Usually NOT eligible if any of the following apply:

  • Exclusion Criteria: Patients who meet any of the following criteria at Screening will not be enrolled in the study:
  • Has persistent clinically significant toxicities (Grade ≥ 2; per NCI CTCAE version 5 from previous anticancer therapy (excluding alopecia which is permitted and excluding Grades 2 and 3 laboratory abnormalities if they are not associated with symptoms, are not considered clinically significant by the investigator, and can be managed with available medical therapies).
  • Has untreated central nervous system (CNS) metastases. Patients with treated CNS metastases are eligible provided imaging demonstrates no new or progressive metastases obtained at least 4 weeks following completion of treatment. CNS imaging during Screening is not required unless clinically indicated.
  • Has an additional malignancy requiring treatment within the past 3 years. Patients with the following concomitant neoplastic diagnoses are eligible: non-melanoma skin cancer, carcinoma in situ, and non-muscle invasive urothelial carcinoma.
  • Poorly controlled hypertension, defined as systolic blood pressure ≥ 160 or diastolic blood pressure ≥ 100 mmHg. Use of anti-hypertensives and rescreening is permitted.
  • A new pulmonary embolism or deep venous thrombosis diagnosed within 3 months prior to randomization.
  • Has a QTcF interval \> 480 msec.
  • New York Heart Association Class III or IV congestive heart failure.
  • Use of prohibited medication within 7 days or 5 half-lives, whichever is shorter, prior to first dose of study drug.

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (38 Sites)

Showing the first 25 of 38 sites.

  • University Of UA Cancer Center(UACC)/DH-SJHMC — Phoenix, Arizona
  • University of California Davis Comprehensive Cancer Center — Sacramento, California
  • UCSF Helen Diller Family Comphrensive Cancer Center - Hemato — San Francisco, California
  • Norton Cancer Institute, Norton Healthcare Pavilion — Louisville, Kentucky
  • Ochsner Clinic Foundation — New Orleans, Louisiana
  • GU Research Network/Urology Cancer Center — Omaha, Nebraska
  • Nebraska Cancer Specialists — Omaha, Nebraska
  • Northwell Health/Monter Cancer Center — Lake Success, New York
  • Mainstreet Physicans Care — Rochester, New York
  • Precision Cancer Research/Dayton Physicians Network - Treatment — Kettering, Ohio
  • Oregon Health and Science University — Portland, Oregon
  • St. Luke's Hospital — Easton, Pennsylvania
  • HOPE Cancer Center of East Texas — Tyler, Texas
  • Medical Oncology Associates, PS (dba Summit Cancer Centers) — Spokane, Washington
  • Beijing Cancer Hospital — Beijing,
  • Zhongshan Hospital Affiliated to Fudan University — Shanghai,
  • Fondazione del Piemonte per l'Oncologia_Istituto di Candiolo, IRCCS_ Oncologia Medica — Candiolo,
  • A.O. Cannizzaro_UOS Oncologia Medica — Catania,
  • IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) UO Oncologia Medica — Meldola (FC),
  • Istituto Europeo di Oncologia_Unità Oncologia Medica Urogenitale e Cervico Facciale — Milan,
  • Istituto Nazionale dei Tumori-Fondazione Pascale- SC Oncologia Medica — Naples,
  • Azienda Ospedaliero-Universitaria Maggiore della Carità Novara_SC Oncologia Medica — Novara,
  • Istituti Clinici Scientifici Maugeri Spa-SB_ UO Oncologia Medica — Pavia,
  • Azienda Ospedaliero Universitaria Pisana_ UO Oncologia Medica Universitaria — Pisa,
  • Fondazione Policlinico Universitario A. Gemelli, U.O.C. Oncologia Medica — Roma,

📞 Contact the Study Coordinator

Phone: (610) 405-5974

Email: sophia.paspal@xynomicpharma.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

  • 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
  • Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
  • Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Renal Cell Carcinoma

Explore by condition: All Renal Cell Carcinoma clinical trials

💡 How to Participate

  1. Check the checklist above to see if you may qualify.
  2. Contact the study coordinator using the phone/email above.
  3. Ask about the visit schedule, what is covered at no cost, and any travel support.
  4. Confirm with your own doctor before making a decision.
🏛️ View Official NIH Record ↗